palovarotene

FDA Drug Profile — SOHONOS

Drug Details

Generic Name
palovarotene
Brand Names
SOHONOS
Application Number
NDA215559
Sponsor
Ipsen Biopharmaceuticals, Inc.
NDC Codes
6
Dosage Forms
CAPSULE, POWDER
Routes
ORAL
Active Ingredients
PALOVAROTENE

Indications and Usage

1 INDICATIONS AND USAGE SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). SOHONOS is a retinoid indicated for reduction in the volume of new heterotopic ossification in adults and children aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP) ( 1 ).